16 September 2026 editorial review · Item
Celregen CRG-002 iPSC-derived islets: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: CRG-002 remains invitation-only, n=10, with estimated January 2028 primary completion. The existing EASD abstract is conference-level evidence, scheduled for 29 September; it is not a completed presentation or peer-reviewed paper. The dynamic abstract could not be fully retrieved in this pass.
- Registry NCT07503028: ENROLLING_BY_INVITATION; updated 2026-08-26; enrollment 10 (ESTIMATED); primary completion 2028-01-18 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: First-in-human transplantation of CRG-002, an iPSC-derived universal islet product for type 1 diabetes (conference).